WO2002099129A2 - Mise au point d'amorces pcr degenerees - Google Patents

Mise au point d'amorces pcr degenerees Download PDF

Info

Publication number
WO2002099129A2
WO2002099129A2 PCT/GB2002/002640 GB0202640W WO02099129A2 WO 2002099129 A2 WO2002099129 A2 WO 2002099129A2 GB 0202640 W GB0202640 W GB 0202640W WO 02099129 A2 WO02099129 A2 WO 02099129A2
Authority
WO
WIPO (PCT)
Prior art keywords
primer
pcr
primer pair
sequences
sequence
Prior art date
Application number
PCT/GB2002/002640
Other languages
English (en)
Other versions
WO2002099129A3 (fr
Inventor
David John Griffiths
Paul Kellam
Robert Anthony Weiss
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to AU2002311446A priority Critical patent/AU2002311446A1/en
Publication of WO2002099129A2 publication Critical patent/WO2002099129A2/fr
Publication of WO2002099129A3 publication Critical patent/WO2002099129A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Definitions

  • the invention relates to a method of designing a panel of primers for detecting viruses in a high throughput polymerase chain reaction assay.
  • Viruses require the use of the cellular- translation and transcription machinery to replicate. In the process of replication they often have deleterious effects on the host cell and thus on the host organism. Viruses constitute an important class of pathogens causing many diseases, leading to loss of life in humans and economic loss in the agricultural industries.
  • the polymerase chain reaction allows the amplification of a specific region of a polynucleotide.
  • the specificity of the reaction is due to the primers which during the course of PCR bind to the region to be amplified in a sequence specific manner.
  • the invention provides a method of designing primers which can be used in high throughput screening to detect viruses. The method may be used to detect unknown viruses which have not yet been sequenced.
  • the invention provides a method of designing a panel of degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said virus family and selectively directs amplification of sequence of said family by PCR, which method comprises
  • each primer in the pair binds a nucleotide sequence that encodes a conserved region identified in (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the nucleotide sequences that encode conserved regions in members of the first virus family, and
  • the invention also provides a method of designing a panel of degenerate primer pairs for screening for new members of multiple known virus families in a biological sample, wherein each primer pair in the panel binds a sequence that is conserved across members of a said virus family and selectively directs amplification of sequence of said family by PCR, which method comprises (a) providing a plurality of nucleotide sequences from members of a first virus family,
  • each primer in the pair binds a conserved region identified in (b) and wherein the primer pair is designed to amplify by PCR the nucleotide sequence between the conserved regions in members of the first virus family, and
  • the invention additionally provides a panel of primers which has been designed by the method of the invention.
  • the invention provides a method of designing a panel of primer pairs which can be used in high throughput virus screening.
  • the method comprises initial steps which deduce the sequences of the primers using computer based calculations, and optional later steps in which the primers are synthesised and tested empirically, for example to determine optimal PCR conditions and/or to select primer pairs with desired further properties.
  • the panel of primers provided by the method are designed to be capable of detecting unknown viruses based on nucleotide and/or amino acid sequences in the unknown virus which are similar (homologous) to nucleotide and/or amino acid sequences in a known virus. These conserved sequences typically have a role in providing a necessary or advantageous activity or property to the virus. conserveed nucleotide sequences may be coding or non-coding sequences.
  • the panel of primers is designed to detect viruses which are single stranded or double stranded DNA or single stranded or double stranded RNA viruses.
  • the viruses are generally capable of infecting prokaryotic or eukaryotic cells, such as bacterial, animal, plant, yeast or fungal cells.
  • the viruses are mammalian (preferably primate) or avian viruses, such as human, pig, horse, sheep, goat, cow, chicken, turkey or duck viruses.
  • the viruses are typically from any combination of the following families: Adenoviridae, Arenaviridae, Arteriviridae, Astroviridae, Bimaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Deltavirus, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polydnaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, Togaviridae or Bornavirus.
  • the primers of the panel are capable of detecting unknown viruses in a biological sample. Such a sample either originates from a single individual or is a pooled sample from individuals of the same species. Thus the panel of primers detects viruses which infect the same species (from which the sample originates).
  • primer pairs designed in the method bind sequence which is conserved across members of a virus family.
  • the panel which is designed in the method may comprise primer pairs that bind sequence which is conserved across substantially all members of the family or across a subset of the members of the family, for example across all members of a subfamily or of a genus.
  • the primer pairs bind at least 70%, at least 80%, or at least 90% of the known viruses of the family, subfamily or genus. Preferably less than 10, such as less than 5, primer pairs will be used for the detection of any given family, subfamily or genus in the panel.
  • the panel of primer pairs is generally capable of detecting viruses from at least 10, 15, 20, 30 or more families, typically up to a maximum of 35 families.
  • the panel of primer pairs may comprise sets of primer pairs which perform a nested PCR reaction.
  • a set of primer pairs comprises a first and second primer pair.
  • the first primer pair is able to amplify a template nucleotide sequence from a virus to form a PCR product.
  • the second primer pair is able to amplify a nucleotide sequence using the PCR product generated by the first primer pair as a template.
  • the use of nested sets of primer pairs allows increased sensitivity.
  • each primer pair is specific for a particular virus family, so that it does not detect viruses of other families .
  • the plurality of amino acid sequences or nucleotide sequences are provided from different known viruses of the same family.
  • the amino acid sequences or nucleotide sequences will be for the same protein of the different viruses. Typically at least 5, 10, 20, 50, 100 or more sequences are provided. The maximum number of sequences provided will, for example, be 300 sequences.
  • Each of the sequences which is provided is typically at least 20, 50, 100, 200 or more amino acids or nucleotides in length.
  • the maximum length of the nucleotide sequences is 1000 nucleotides and the maximum length of the amino acid sequences is 300 amino acids.
  • the sequences may be obtained from a database of sequences, such as GenBank.
  • the sequences may be obtained from a database comprising virus sequences which are organised into homologous protein families (based on sequence similarity relationships).
  • sequences are obtained from the VTDA database (described in Alba et al (2001) Nucleic Acids Research 29, 133-136) or the Virus Division of GenBank.
  • the sequences may be provided in the form of a database, preferably in computer-readable form.
  • the sequences are preferably provided in the form of a computer-readable database constructed using programs which identify homologous protein families, such as GeneTableMaker, MKDOM or PSCBuilder.
  • conserved regions typically such conserved regions will have a length of at least 12 nucleotides, such as at least 15, 21, 27, 36, 99 or more nucleotides (generally up to a maximum length of 200 nucleotides) or at least 4, 5, 7, 10, 25 or more amino acids (generally up to a maximum length of 50 amino acids).
  • the virus sequences which are being provided will of course share identity or similarity.
  • the amino acids or nucleotides in at least 50% of the positions in the region will be the same in at least 50 %, 60%, 70%, or 80% of the viruses of the group (i.e. in the family, genus or subfamily).
  • the algorithm which identifies conserved regions generally uses a multiple sequence alignment method.
  • the method may comprise (a) aligning all pairs of sequences separately to calculate a distance matrix giving the divergence of each pair of sequences, (b) calculating a guide tree from the distance matrix, and (c) aligning the sequences progressively according to the branching order in the guide tree.
  • a preferred algorithm for the aligning the conserved sequences is CLUSTALW as described in Thompson et al (1994) Nucleic Acids Research 22, 4673-80.
  • Other algorithms that can be used for aligning sequences are MultAlin (Corpet (1988) Nucleic Acids Research 16, 10881-90) or Jalview (Clamp et al (1998) http://barton.ebi.co.uk).
  • BLOCKS of conserved regions of amino acids may be extracted from the multiple alignments, typically using the program Blocks Multiple Alignment Processor. Alternatively the entire process of performing multiple alignments and extracting BLOCKS can be performed using BLOCKMAKER (Henikoff and Henikoff (1994) Genomics 19, 97-107).
  • the output from the alignment and BLOCK extraction set i.e. the information describing the identified conserved regions
  • Such output is typically in the form of partial sequences which correspond to the conserved regions (BLOCKS).
  • BLOCKS are input into a primer design algorithm. In one embodiment such an algorithm is CODEHOP.
  • the conserved regions which are chosen as targets for primers preferably comprise few codohs with degenerate counterparts, i.e. preferably the sequence has a low redundancy, such as a redundancy of less than 512 fold, 256 fold or 128 fold.
  • Each primer binds in accordance with Watson-Crick base pairing and thus the binding is sequence specific.
  • Each primer will thus be designed to be wholly or partially complementary to the sequence to which it binds.
  • Each of the primers typically has a length of at least 8 nucleotides, such as at least 10, 12, 15, 20, 30, 40 or more nucleotides (up to a maximum of 50 nucleotides for example).
  • the primer may. comprises at least 2, 4 or 6, up to a maximum of 10 for example, inosine bases. Inosine is able to bind to any of the four nucleotides and therefore use of inosine causes a reduction in effective redundancy.
  • Each primer pair will be designed so that the PCR product generally has a length of at least 20, such as at least 50, 100, 200, 500, 1000 or more nucleotides (and typically up to a maximum of 5xl0 3 nucleotides long).
  • Each primer is preferably designed so that it anneals to a single site, i.e. the primer will not bind to any other site in the genome of the relevant virus.
  • Each primer is preferably designed so that it does not exhibit secondary structure, i.e. the nucleotides in the primer will not bind substantially to any other nucleotide in the primer apart from those to which it is covalently linked.
  • each primer is designed so that it does not bind other primers with the same sequence.
  • the 3' region, and preferably the 3' terminal nucleotide of the primer binds to the target sequence with high affinity, thus preferably this region or nucleotide comprises a G or C.
  • each primer is designed to have an annealing temperature of from 30 to 65 ° C, such as 50 to 60 ° C or 35 to 45 ° C.
  • each primer pair may be designed to ensure that the two primers do not bind to each other.
  • such an algorithm designs primers according to the following rules:
  • a set of blocks is input, where a block is an aligned array of amino acid sequence segments without gaps that represents a highly conserved region of homologous proteins.
  • a weight is provided for each sequence segment, which can be increased to favour the contribution of selected sequences in designing the primer.
  • a codon usage table is chosen for the target genome.
  • PSSM amino acid position-specific scoring matrix
  • step 4 For each position of the block, the most common codon corresponding to the amino acid chosen in step 3 is selected utilizing the user-selected codon usage table. This selection is used for the default 5' consensus clamp in step 8. 5)
  • a DNA PSSM is calculated from the amino acid matrix (step 2) and the codon usage table.
  • the DNA matrix has three positions for each position of the amino acid matrix.
  • the score for each amino acid is divided among its codons in proportion to their relative weights from the codon usage table, and the scores for each of the four different nucleotides are combined in each DNA matrix position. Nucleotide positions are treated independently when the scores are combined. As an option, the highest scoring nucleotide residue from each position can replace the most common codons from step 4 that are used in the consensus clamp.
  • the degeneracy is determined at each position of the DNA matrix based on the number of bases found there.
  • a weight threshold can be specified such that bases that contribute less than a minimum weight are ignored in determining degeneracy.
  • Possible degenerate core regions are identified by scanning the DNA matrix in the 3' to 5' direction.
  • a core region must start on an invariant 3' nucleotide position, have length of 11 or 12 positions ending on a codon boundary, and have a maximum degeneracy of 128 (this is the default setting of CODEHOP).
  • the degeneracy of a region is the product of the number of possible bases in each position.
  • Candidate degenerate core regions are extended by addition of a 5' consensus clamp from step 4 or 5.
  • the length of the clamp is controlled by a melting point temperature calculation (the CODEHOP default is 60 °C) and is usually about 20 nucleotides. 9) Steps 7 and 8 are repeated on the reverse complement of the DNA matrix from step 5 for primers corresponding to the opposite DNA strand.
  • CODEHOP Rose et al (1998) Nucleic Acids Research 26, 1628- 1635) is used to design the primer pairs. This program uses the above rules.
  • the primers designed by the algorithm may then be mapped back to the original sequence to choose primer pairs which provide the desired length of PCR product.
  • primer pairs can then be synthesised and tested. They are typically tested to determine the optimal conditions for using the primers in a PCR reaction.
  • the PCR reaction is carried out in a PCR mixture that generally comprises the following: the template polynucleotide (which will be amplified in the event of virus detection), one or more primer pairs designed as described above, a polymerase enzyme (typically a DNA polymerase, such as Taq polymerase), deoxynucleotide triphosphates (dATP, dTTP, dCTP and dGTP) and a suitable buffer.
  • a polymerase enzyme typically a DNA polymerase, such as Taq polymerase
  • deoxynucleotide triphosphates dATP, dTTP, dCTP and dGTP
  • the PCR reaction generally comprises cycles of the following steps: a denaturation step, a primer annealing step and a polynucleotide synthesis step.
  • the PCR reaction comprises at least 25 cycles, such as 30, 35, 40 or more cycles, up to a maximum of 60 cycles for example.
  • the PCR mixture is heated to a temperature at which the polynucleotides in the PCR mixture (in particular the polynucleotide region to be amplified) denature to single stranded form.
  • the denaturing temperature is generally from 85 to 98 "C.
  • the primers bind to template nucleotide sequence in a sequence specific manner.
  • This step is generally carried out at a temperature of from 30 to 65 °C.
  • the polymerase replicates/synthesises nucleotide sequence based on template sequence by addition of nucleotides to the 3' end of the bound primers. This step is generally carried out at about 72 ⁇ 0
  • the primers are tested for their ability to amplify one or more of the plurality of nucleotide sequences from known viruses which were used to design the primers, or in the case of amino acid sequences from known viruses being used to design the primers the primers may be tested for their ability to amplify the nucleotide sequence from the virus which encodes the amino acid sequence.
  • the primers may be tested in a range of buffer conditions to determine optimal buffer conditions for PCR using the primers.
  • the buffer conditions which may be tested include pH (typically between 7 and 10), magnesium concentration (typically from 0.5 M to 5 mM), potassium chloride (typically from 0 to 100 mM), ammonium chloride (typically 0 to 100 mM), glycerol (typically 0 to 20%), dimethysulphoxide (typically 0 to 20%), ethanol (typically 0 to 20%), sorbitol (typically 0 to 20%) or betaine (typically 1M betaine).
  • pH typically between 7 and 10
  • magnesium concentration typically from 0.5 M to 5 mM
  • potassium chloride typically from 0 to 100 mM
  • ammonium chloride typically 0 to 100 mM
  • glycerol typically 0 to 20%
  • dimethysulphoxide typically 0 to 20%
  • ethanol typically 0 to 20%
  • sorbitol typically 0 to 20%
  • betaine typically 1M betaine
  • the primers may be tested at a range of different temperatures to determine the optimal temperatures in the PCR reaction.
  • the primers are tested in PCR reaction in which a range of primer annealing temperatures are tested.
  • the range of temperatures is from 30 to 65 ° C .
  • the panel of primer pairs or a group of primers within the panel may be designed to be used together on the same plate (i.e. using the same thermal cycles). Thus such primer pairs will be designed to work at the same annealing temperature.
  • a group of primer pairs within the panel are designed to have similar optimal conditions for use in PCR so that they can be used optimally in the same well or reaction vessel, i.e. that they can be used in multiplex PCR.
  • Such a group typically comprises at least 2, 3, 4, 5, 6 or more primer pairs (up to a maximum of 8 primer pairs for example).
  • the computer based method steps may be used to design primer pairs which are calculated to have similar annealing temperatures and/or the primers are tested to select primer pairs which can be used optimally together. Such testing typically determines whether the primers work optimally with the same buffers and/or whether the primers have similar annealing temperatures.
  • At least one or both primers of each primer pair in the group carries a label. Typically at least one of the primers in each primer pair will carry a different label from that used for the other primer pairs.
  • the PCR product generated by labelled primers carries the labels present on the primers. Thus after the group of primers have been used for PCR in the same well detection of the labels in the PCR products can be used to deduce which PCR product was formed from each primer pair.
  • all forward primers of the group are labelled with one colour and the reverse primers are labelled with a different colour.
  • the primers are labelled with a fluorescent label, such as fluorescein based labels (e.g. fluorescein isothiocyanate).
  • a fluorescent label such as fluorescein based labels (e.g. fluorescein isothiocyanate).
  • fluorescein based labels e.g. fluorescein isothiocyanate
  • Different primer pairs may be labelled with fluorescent labels of different colours.
  • the fluorescent labels which are used may be capable of detection by a Beckman CEQ2000TM or Applied Biosystems A3700TM fluorescent DNA analyser.
  • the fluorescent labels may obtained from Beckman Coulter or Applied Biosystems.
  • each PCR product which is generated by the group of primers differs in size from all the other PCR products by at least 20, such as at least 50, 100, 200, 500, 1000 or more nucleotides.
  • Each PCR product may for example differ in size from all other PCR products by up to a maximum of 3000 nucleotides.
  • Example 1 illustrates the invention.
  • a panel of primers was designed for detecting unknown viruses from the family Herpesviridae according to the strategy shown in Figure 1.
  • the amino acid sequences of herpes virus DNA packaging protein UL15 were obtained from the VTDA database (Alba et al, see above). These sequences are shown in Table 1. The sequences obtained from the VTDA database were then imported into
  • CLUSTALW This compares the protein sequences to identify conserved regions and then aligns the sequences according to the conserved regions.
  • the alignment produced by CLUSTALW is shown in Table 2.
  • the BLOCKMAKER program was then used to extract blocks of conserved aligned sequences which do not contain gaps from CLUSTALW and enter them into CODEHOP.
  • the primer sequences were then designed by CODEHOP using the conserved sequences.
  • the output from the CODEHOP program is shown in Table 3.
  • the 'Complement of Block' sequences shown in Table 3 shows the sequence of the other strand allowing primers to be designed for amplification in the opposite direction.
  • RVKAHTNATSCSCYIIJNKPVFITI DGAMRNTAELF PDSFMQEI IGGGNISGAHRDEPVFTKTAQDRF Ii

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de mise au point d'amorces PCR pour le criblage de nouveaux membres de familles de virus connues.
PCT/GB2002/002640 2001-06-07 2002-06-07 Mise au point d'amorces pcr degenerees WO2002099129A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002311446A AU2002311446A1 (en) 2001-06-07 2002-06-07 Designing degenerate pcr primers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113908.8 2001-06-07
GB0113908A GB0113908D0 (en) 2001-06-07 2001-06-07 Designing degenerate PCR primers

Publications (2)

Publication Number Publication Date
WO2002099129A2 true WO2002099129A2 (fr) 2002-12-12
WO2002099129A3 WO2002099129A3 (fr) 2003-09-18

Family

ID=9916128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002640 WO2002099129A2 (fr) 2001-06-07 2002-06-07 Mise au point d'amorces pcr degenerees

Country Status (3)

Country Link
AU (1) AU2002311446A1 (fr)
GB (1) GB0113908D0 (fr)
WO (1) WO2002099129A2 (fr)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099130A2 (fr) * 2001-06-07 2002-12-12 University College London Detection de virus au moyen d'amorces pcr degenerees
WO2006094238A2 (fr) * 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions utilisees pour identifier des virus secondaires
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10961585B2 (en) 2018-08-08 2021-03-30 Pml Screening, Llc Methods for assessing risk of developing a viral of disease using a genetic test
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478724A (en) * 1991-08-16 1995-12-26 The Rockefeller University Lentivirus-specific nucleotide probes and methods of use
US5639871A (en) * 1988-09-09 1997-06-17 Roche Molecular Systems, Inc. Detection of human papillomavirus by the polymerase chain reaction
EP1013776A1 (fr) * 1998-12-22 2000-06-28 Universiteit van Amsterdam Méthode sensible d'essai pour la détection ou pour la quantification d'acide nucléique de cytomégalovirus humain
US6168917B1 (en) * 1996-10-02 2001-01-02 The United States Of America As Represented By The Department Of Health And Human Services Detection and identification of non-polio enteroviruses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639871A (en) * 1988-09-09 1997-06-17 Roche Molecular Systems, Inc. Detection of human papillomavirus by the polymerase chain reaction
US5478724A (en) * 1991-08-16 1995-12-26 The Rockefeller University Lentivirus-specific nucleotide probes and methods of use
US6168917B1 (en) * 1996-10-02 2001-01-02 The United States Of America As Represented By The Department Of Health And Human Services Detection and identification of non-polio enteroviruses
EP1013776A1 (fr) * 1998-12-22 2000-06-28 Universiteit van Amsterdam Méthode sensible d'essai pour la détection ou pour la quantification d'acide nucléique de cytomégalovirus humain

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBA M MAR ET AL: "VIDA: A virus database system for the organization of animal virus genome open reading frames." NUCLEIC ACIDS RESEARCH, vol. 29, no. 1, 1 January 2001 (2001-01-01), pages 133-136, XP002249137 ISSN: 0305-1048 *
ROSE T M ET AL: "Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 7, 1998, pages 1628-1635, XP002141299 ISSN: 0305-1048 cited in the application *
STEPHENSEN C B ET AL: "Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay" VIRUS RESEARCH, AMSTERDAM, NL, vol. 60, no. 2, April 1999 (1999-04), pages 181-189, XP002242737 ISSN: 0168-1702 *
THOMPSON J D HIGGENS D G GIBSON T J: "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 22, November 1994 (1994-11), pages 4673-4680, XP002956304 ISSN: 0305-1048 *
VOELTER C ET AL: "Screening human tumor samples with a broad-spectrum polymerase chain reaction method for the detection of polyomaviruses" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 237, no. 2, 27 October 1997 (1997-10-27), pages 389-396, XP002242736 ISSN: 0042-6822 *

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802372B2 (en) 2001-03-02 2014-08-12 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US9416424B2 (en) 2001-03-02 2016-08-16 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US9752184B2 (en) 2001-03-02 2017-09-05 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US8563250B2 (en) 2001-03-02 2013-10-22 Ibis Biosciences, Inc. Methods for identifying bioagents
US8268565B2 (en) 2001-03-02 2012-09-18 Ibis Biosciences, Inc. Methods for identifying bioagents
US8265878B2 (en) 2001-03-02 2012-09-11 Ibis Bioscience, Inc. Method for rapid detection and identification of bioagents
US8017358B2 (en) 2001-03-02 2011-09-13 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents
US8214154B2 (en) 2001-03-02 2012-07-03 Ibis Biosciences, Inc. Systems for rapid identification of pathogens in humans and animals
US8815513B2 (en) 2001-03-02 2014-08-26 Ibis Biosciences, Inc. Method for rapid detection and identification of bioagents in epidemiological and forensic investigations
WO2002099130A2 (fr) * 2001-06-07 2002-12-12 University College London Detection de virus au moyen d'amorces pcr degenerees
WO2002099130A3 (fr) * 2001-06-07 2003-09-04 Univ London Detection de virus au moyen d'amorces pcr degenerees
US8380442B2 (en) 2001-06-26 2013-02-19 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8921047B2 (en) 2001-06-26 2014-12-30 Ibis Biosciences, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US8298760B2 (en) 2001-06-26 2012-10-30 Ibis Bioscience, Inc. Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby
US9725771B2 (en) 2002-12-06 2017-08-08 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8822156B2 (en) 2002-12-06 2014-09-02 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8476415B2 (en) 2003-05-13 2013-07-02 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8013142B2 (en) 2003-09-11 2011-09-06 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US7956175B2 (en) 2003-09-11 2011-06-07 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US9447462B2 (en) 2004-02-18 2016-09-20 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8187814B2 (en) 2004-02-18 2012-05-29 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8987660B2 (en) 2004-05-24 2015-03-24 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US9449802B2 (en) 2004-05-24 2016-09-20 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8173957B2 (en) 2004-05-24 2012-05-08 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by digital thresholding
US8407010B2 (en) 2004-05-25 2013-03-26 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA
US9873906B2 (en) 2004-07-14 2018-01-23 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006094238A2 (fr) * 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions utilisees pour identifier des virus secondaires
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
WO2006094238A3 (fr) * 2005-03-03 2007-02-08 Isis Pharmaceuticals Inc Compositions utilisees pour identifier des virus secondaires
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8551738B2 (en) 2005-07-21 2013-10-08 Ibis Biosciences, Inc. Systems and methods for rapid identification of nucleic acid variants
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US10529441B2 (en) 2006-05-03 2020-01-07 Population Bio, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8871471B2 (en) 2007-02-23 2014-10-28 Ibis Biosciences, Inc. Methods for rapid forensic DNA analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8252599B2 (en) 2008-09-16 2012-08-28 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US9027730B2 (en) 2008-09-16 2015-05-12 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US9023655B2 (en) 2008-09-16 2015-05-05 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8609430B2 (en) 2008-09-16 2013-12-17 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US8796617B2 (en) 2009-02-12 2014-08-05 Ibis Biosciences, Inc. Ionization probe assemblies
US9165740B2 (en) 2009-02-12 2015-10-20 Ibis Biosciences, Inc. Ionization probe assemblies
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US11788142B2 (en) 2010-08-02 2023-10-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11339439B2 (en) 2011-10-10 2022-05-24 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11174516B2 (en) 2012-02-09 2021-11-16 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
US12012634B2 (en) 2012-09-14 2024-06-18 Population Bio, Inc. Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism
US11008614B2 (en) 2012-09-14 2021-05-18 Population Bio, Inc. Methods for diagnosing, prognosing, and treating parkinsonism
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10597721B2 (en) 2012-09-27 2020-03-24 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US11618925B2 (en) 2012-09-27 2023-04-04 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US11549145B2 (en) 2014-09-05 2023-01-10 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10544463B2 (en) 2017-02-03 2020-01-28 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10941448B1 (en) 2017-02-03 2021-03-09 The Universite Paris-Saclay Methods for assessing risk of developing a viral disease using a genetic test
US10563264B2 (en) 2017-02-03 2020-02-18 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US11913073B2 (en) 2017-02-03 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US10961585B2 (en) 2018-08-08 2021-03-30 Pml Screening, Llc Methods for assessing risk of developing a viral of disease using a genetic test
US11913074B2 (en) 2018-08-08 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US12054778B2 (en) 2018-08-08 2024-08-06 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test

Also Published As

Publication number Publication date
WO2002099129A3 (fr) 2003-09-18
GB0113908D0 (en) 2001-08-01
AU2002311446A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
WO2002099129A2 (fr) Mise au point d'amorces pcr degenerees
Meng et al. Virome analysis of tick-borne viruses in Heilongjiang Province, China
Boubourakas et al. Sensitive and rapid detection of peach latent mosaic viroid by the reverse transcription loop-mediated isothermal amplification
Tsai et al. Development of a loop-mediated isothermal amplification for rapid detection of orf virus
Sabanadzovic et al. Southern tomato virus: the link between the families Totiviridae and Partitiviridae
Moreno et al. Reference genes for reliable potyvirus quantitation in cassava and analysis of Cassava brown streak virus load in host varieties
WO2002099130A2 (fr) Detection de virus au moyen d'amorces pcr degenerees
Hajizadeh et al. Development and validation of a multiplex RT-PCR method for the simultaneous detection of five grapevine viroids
CN105555972A (zh) 遗传测定
CA2925942C (fr) Detection d'acides nucleiques microbiologiques rares
Fauver et al. A reverse-transcription/RNase H based protocol for depletion of mosquito ribosomal RNA facilitates viral intrahost evolution analysis, transcriptomics and pathogen discovery
WO2009098789A1 (fr) Procédé de détection d'un virus pathogène dans un crustacé par la méthode lamp et coffret de réactifs pour la détection
Aimone et al. An experimental strategy for preparing circular ssDNA virus genomes for next-generation sequencing
Sahin et al. Novel and divergent bipartite mycoviruses associated with the ectomycorrhizal fungus Sarcosphaera coronaria
Zhang et al. Deep sequencing of banana bract mosaic virus from flowering ginger (Alpinia purpurata) and development of an immunocapture RT-LAMP detection assay
JP6436598B1 (ja) イチゴの病原ウイルス由来の核酸を特異的に増幅するためのプライマーセットおよびイチゴの病原ウイルスの検出方法
Mathijs et al. Using genomics for surveillance of veterinary infectious agents
Kleynhans et al. Comparison of multiple viral population characterization methods on a candidate cross-protection Citrus tristeza virus (CTV) source
Lin et al. Development of an EvaGreen based real-time RT-PCR assay for rapid detection, quantitation and diagnosis of goose calicivirus
JP6027023B2 (ja) 多価輸送熱ワクチンのウイルス成分を同定し、識別するための組成物および方法
Shaffer et al. First report of amazon lily mild mottle virus in peony in the United States
Leisova‐Svobodova et al. Detection of Garlic Viruses Using SYBR Green Real‐time Reverse Transcription‐Polymerase Chain Reaction
Song et al. RT-PCR-RFLP for genetic diversity analysis of the citrus tatter leaf virus strain of Apple stem grooving virus
JP2016524906A (ja) アレルギーを引き起こすダニのｐｃｒによる分子同定
EP4308726A2 (fr) Compositions et procédés pour détecter des variants de coronavirus 2 à syndrome respiratoire aigu sévère (sars-cov-2) ayant des mutations de protéine spike

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP